Why Recursion Pharmaceuticals Stock Caught a Cold This Week

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (NASDAQ: RXRX) stock was shedding more than 17% of its value week-to-date as of Thursday night.The company was the target of an analyst price target cut. On top of that, regulatory filings revealed that several of the clinical-stage biotech's executives had sold large piles of stock. The analyst wielding the scissors was Sean Laaman from white-shoe investment bank Morgan Stanley (NYSE: MS). On Tuesday, he shaved $0.20 per share from his fair value assessment to a new level of $4.80, and maintained his equalweight (hold, in other words) recommendation on the stock. Detailed information on Laaman's latest Recursion take weren't immediately available. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool